Efficacy of plasma therapy in atypical hemolytic uremic syndrome with complement factor H mutations.
about
Atypical hemolytic uremic syndromeaHUS caused by complement dysregulation: new therapies on the horizon.Atypical hemolytic-uremic syndrome in a child presenting with malignant hypertension.Plasma therapy for atypical haemolytic uraemic syndrome associated with heterozygous factor H mutations.Assesment, treatment and prevention of atypical hemolytic uremic syndrome.Manipulating the mediator: modulation of the alternative complement pathway C3 convertase in health, disease and therapy.
P2860
Efficacy of plasma therapy in atypical hemolytic uremic syndrome with complement factor H mutations.
description
2008 nî lūn-bûn
@nan
2008 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
name
Efficacy of plasma therapy in ...... complement factor H mutations.
@ast
Efficacy of plasma therapy in ...... complement factor H mutations.
@en
type
label
Efficacy of plasma therapy in ...... complement factor H mutations.
@ast
Efficacy of plasma therapy in ...... complement factor H mutations.
@en
prefLabel
Efficacy of plasma therapy in ...... complement factor H mutations.
@ast
Efficacy of plasma therapy in ...... complement factor H mutations.
@en
P2093
P1433
P1476
Efficacy of plasma therapy in ...... complement factor H mutations.
@en
P2093
Anne-Laure Lapeyraque
Aïcha Merouani
Eric Wagner
Marie-José Clermont
Pierre Robitaille
Timothy H J Goodship
Véronique Frémeaux-Bacchi
Véronique Phan
P2888
P304
P356
10.1007/S00467-008-0803-4
P577
2008-04-19T00:00:00Z
P6179
1047093494